Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 10/20 | 0.85 |
| ▸ | MAPK8 | P45983 | 10/20 | 0.64 |
| ▸ | MAPK9 | P45984 | 10/20 | 0.64 |
| ▸ | JUN | P05412 | 9/20 | 0.64 |
| ▸ | CDK2 | P24941 | 9/20 | 0.64 |
| ▸ | MAPK10 | P53779 | 6/20 | 0.64 |
| ▸ | CCNK | O75909 | 1/20 | 0.60 |
| ▸ | CCNH | P51946 | 1/20 | 0.60 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.60 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16665165 | 0.92 | CDK7 (1.00) | CDK7MAPK8MAPK9JUNCDK2 | |
| SCHEMBL16665084 | 0.92 | CDK7 (1.00) | CDK7MAPK8MAPK9JUNCDK2 | |
| SCHEMBL22778392 | 0.92 | CDK7 (1.00) | CDK7MAPK8MAPK9JUNCDK2 | |
| SCHEMBL23289869 | 0.91 | CDK7 (0.71) | CDK7MAPK8MAPK9JUNCDK2 | |
| SCHEMBL17688423 | 0.91 | CDK7 (0.71) | CDK7MAPK8MAPK9JUNCDK2 | |
| SCHEMBL16655427 | 0.91 | CDK7 (0.78) | CDK7MAPK8MAPK9JUNCDK2 | |
| SCHEMBL17688417 | 0.90 | CDK7 (0.87) | CDK7MAPK8MAPK9JUNCDK2 | |
| SCHEMBL17696266 | 0.90 | CDK7 (0.87) | CDK7MAPK8MAPK9JUNCDK2 | |
| SCHEMBL16665088 | 0.90 | CDK7 (0.87) | CDK7MAPK8MAPK9JUNCDK2 | |
| SCHEMBL17696258 | 0.90 | CDK7 (0.87) | CDK7MAPK8MAPK9JUNCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292167-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2019-09-26 | — | — | US | disclosed |
| WO-2019035866-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBEROUS SCLEROSIS COMPLEX | THE BRIGHAM & WOMEN'S HOSPITAL, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292167-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CDK7, CDK3, CDK17 | CDK7 1/4885MAPK8 352/4885MAPK9 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.